---
figid: PMC4264417__fonc-04-00360-g003
figtitle: Notch–EGFR crosstalk in TNBC
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
- Human papillomavirus type 16
organisms_ner:
- Drosophila melanogaster
- Mus musculus
- Homo sapiens
- Rattus norvegicus
pmcid: PMC4264417
filename: fonc-04-00360-g003.jpg
figlink: /pmc/articles/PMC4264417/figure/F3/
number: F3
caption: Notch–EGFR crosstalk in TNBC. Dong et al. ascertained a form of crosstalk
  between EGFR and Notch receptors that enabled resistance to EGFR targeted therapy,
  gefitinib, in TNBC cells. It is proposed that EGFR targeted resistance occurs by
  Notch-1-mediated activation of the AKT pathway. Notch–EGFR crosstalk facilitates
  an increase in serine-473 residue phosphorylation of AKT, which allows TNBC cells
  to survive EGFR targeted treatments. Dual inhibition of EGFR via the tyrosine kinase
  inhibitor (TKI) gefitinib and the Notch pathway by GSIs, N-[N- (3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine
  t-butyl ester (DAPT) in vitro, and compound E in vivo, are synergistically lethal
  to TNBC tumorigenesis.
papertitle: Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer.
reftext: Andrew T. Baker, et al. Front Oncol. 2014;4:360.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9377133
figid_alias: PMC4264417__F3
figtype: Figure
redirect_from: /figures/PMC4264417__F3
ndex: 0a4960c7-deb1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4264417__fonc-04-00360-g003.html
  '@type': Dataset
  description: Notch–EGFR crosstalk in TNBC. Dong et al. ascertained a form of crosstalk
    between EGFR and Notch receptors that enabled resistance to EGFR targeted therapy,
    gefitinib, in TNBC cells. It is proposed that EGFR targeted resistance occurs
    by Notch-1-mediated activation of the AKT pathway. Notch–EGFR crosstalk facilitates
    an increase in serine-473 residue phosphorylation of AKT, which allows TNBC cells
    to survive EGFR targeted treatments. Dual inhibition of EGFR via the tyrosine
    kinase inhibitor (TKI) gefitinib and the Notch pathway by GSIs, N-[N- (3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine
    t-butyl ester (DAPT) in vitro, and compound E in vivo, are synergistically lethal
    to TNBC tumorigenesis.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - her
  - Hesr
  - Akt
  - osa
  - nej
  - Coa
  - Su(H)
  - .na.character
  - Egf
  - Erbb2
  - Akt1
  - Ep300
  - Hps3
  - Rbpj
  - Notch1
  - EGF
  - ERBB2
  - EGFR
  - AKT1
  - AKT2
  - AKT3
  - EP300
  - RBPJ
  - NOTCH1
  - Ser
  - Thr
  - Tyr
---
